이상반응 보고
| VAERS ID | 2247536 |
|---|---|
| 성별 | 남성 |
| 나이 | 30세 |
| 주 코드 | FR |
| 제약회사 | MODERNA |
| 로트 번호 | |
| 예방접종 횟수 | 3 |
| 접종일 | 2022-02-18 |
| 발병일 | 2022-03-14 |
| 상태 | 입원 |
증상
- 횡단 척수염(Myelitis transverse)
이환 중 질병
지병
기타 의료
이전 예방접종
알레르기
임상 검사
증상 상세
Transverse myelitis; This regulatory authority case was reported by an other health care professional and describes the occurrence of MYELITIS TRANSVERSE (Transverse myelitis) in a 30-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
No Medical History information was reported.
On 18-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.
On 14-Mar-2022, the patient experienced MYELITIS TRANSVERSE (Transverse myelitis) (seriousness criterion hospitalization).
At the time of the report, MYELITIS TRANSVERSE (Transverse myelitis) was resolving.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
On 13-Mar-2022, the left foot became numb and weak.
In the next fewdays, the symptoms progressed to weakness and numbness of both legs, difficulty in walking and difficulty in urination and defecation.
On 14-Mar-2022, patient went to hospital for emergency treatment and was admitted to the hospital for examination and treatment on the same day.
Patient's thoracic MRI showed thoracic spinal cord lesions, which were diagnosed as transverse spinal cord inflammation in a series of examinations.
This was a 30 year old male had no notable underlying disease.
This time the patient came to ER for having acute onset of left lower limbs weakness for two days.
He also complained of having numbness at lower abdominal area (Sensory level: T11-T12).
He also had difficulty of urination.
He denied of having trauma, pain, fever or insect bite.
Therefore, insert the Foley and arrange MRI to rule out epidural compression syndrome which revealed no obvious compression lesion but with hyperintensity in T11/12 myelopathy.
Under the impression of T spine myelopathy we thus admitted the patient to the ward for further evaluation.
On 15-Mar to 18-Mar-2022, patient received high dose steroids (pulse therapy) On 21-Mar to 25-Mar-2022 patient had received immunoglobulin treatment.
On 8-Apr-2022 patient's symptoms improved partially after treatment and rehabilitation.
At present, walking aids are still needed for the patient to stand, and there are persistent symptoms of difficult urination and defecation.
Concomitant medications were not reported.
Company Comment: This regulatory authority case concerns a 30-year-old male patient with no reported medical history unexpected, serious (Hospitalization) adverse event of special interest Transverse Myelitis 3 weeks and 3 days after vaccination with a third dose of mRNA-1273.
3 weeks and 3 days after vaccination with a third dose of mRNA-1273, patient complained of left lower limbs weakness for two days and numbness at lower abdominal area (Sensory level: T11-T12).
He also had difficulty of urination.
He sought consult in the hospital wherein Foley catheter was inserted, and magnetic resonance imaging done revealed no obvious compression lesion but with hyperintensity in T11/12 myelopathy.
He was admitted in the hospital and received high dose steroids (pulse therapy) and immunoglobulin treatment.
The symptoms improved partially after treatment and rehabilitation.
At present, walking aids are still needed for the patient to stand, and there are persistent symptoms of difficult urination and defecation.
The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.
Sender's Comments: This regulatory authority case concerns a 30-year-old male patient with no reported medical history unexpected, serious (Hospitalization) adverse event of special interest Transverse Myelitis 3 weeks and 3 days after vaccination with a third dose of mRNA-1273.
3 weeks and 3 days after vaccination with a third dose of mRNA-1273, patient complained of left lower limbs weakness for two days and numbness at lower abdominal area (Sensory level: T11-T12).
He also had difficulty of urination.
He sought consult in the hospital wherein Foley catheter was inserted, and magnetic resonance imaging done revealed no obvious compression lesion but with hyperintensity in T11/12 myelopathy.
He was admitted in the hospital and received high dose steroids (pulse therapy) and immunoglobulin treatment.
The symptoms improved partially after treatment and rehabilitation.
At present, walking aids are still needed for the patient to stand, and there are persistent symptoms of difficult urination and defecation.
The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Events' seriousness was assessed as per Regulatory Authority's report.